1. Novartis Ag (21 from 3,923 patents)

2. Respivert Limited (3 from 63 patents)

3. Isis Pharmaceuticals, Inc. (2 from 1,035 patents)

4. Other (1 from 832,680 patents)

5. Irm LLC (1 from 151 patents)

6. Modern Biosciences Limited (1 from 2 patents)

7. Novartis Pharma Gmbh (8 patents)

1. 12162836 - N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use

2. 11208381 - Indole derivatives and their use as protein kinase inhibitors

3. 11046672 - Indolinones compounds and their use in the treatment of fibrotic diseases

4. 10669235 - Indole derivatives and their use as protein kinase inhibitors

5. 9751876 - Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension

6. 9643983 - Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives

7. 9139586 - Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives

8. 9073921 - Salt forms of bicyclic heterocyclic derivatives

9. 9034879 - Heterocyclic compounds for the treatment of CF

10. 8883819 - Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension

11. 8697687 - Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives

12. 8664228 - 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of airway diseases

13. 8318935 - Organic compounds 75074

14. 8236808 - Pyrazine derivatives as ENAC blockers

15. 8168654 - Quinuclidine derivatives binding to mucarinic M3 receptors